Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Ayala Pharmaceuticals Inc ADXS

Healthcare Biotechnology
Ayala Pharmaceuticals, Inc. is a clinical-stage oncology company primarily focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations. The Company's lead candidate is aspacytarabine (BST-236), a novel anti-metabolite for first line treatment in unfit acute myeloid leukemia... see more

Recent & Breaking News (PINL:ADXS)

Gynecologic Oncology Group (GOG) Phase 2 Study of Advaxis's Lm-LLO Immunotherapy, ADXS-HPV, for the Treatment of Persistent or Recurrent Cervical Cancer Achieves Safety and Efficacy Criteria

GlobeNewswire January 28, 2015

Harwood Feffer LLP Announces Investigation of Advaxis, Inc.

PR Newswire January 23, 2015

Federman & Sherwood Investigates Advaxis, Inc. For Possible Violations of Federal Securities Laws

Business Wire January 22, 2015

ADXS SHAREHOLDER ALERT: The Law Firm of Levi & Korsinsky, LLP Launches an Investigation into Possible Violations of Federal Securities Laws by the Board of Directors of Advaxis, Inc.

Business Wire January 22, 2015

Advaxis Announces FDA Acceptance of Its Investigational New Drug Application to Commence First-in-Human Clinical Trials of ADXS-HER2

GlobeNewswire January 22, 2015

SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Advaxis, Inc.

PR Newswire January 22, 2015

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Advaxis, Inc. - ADXS

PR Newswire January 22, 2015

EQUITY ALERT: The Rosen Law Firm Announces Investigation of Securities Claims Against Advaxis, Inc. - ADXS

Business Wire January 21, 2015

ADXS Shareholder Alert: The Law Firm of Wohl & Fruchter LLP Announces Investigation of Advaxis, Inc.

Business Wire January 21, 2015

Advaxis to Host Analyst & Investor Day on February 3, 2015

GlobeNewswire January 20, 2015

Advaxis to Present at the Noble Financial Capital Markets 11th Annual Investor Conference

GlobeNewswire January 15, 2015

MarketExclusive.com - H.C. Wainwright & Co. Raises Price Target of Advaxis, Inc.

Accesswire January 13, 2015

Advaxis Provides 2014 Year-End Review and 2015 Outlook

GlobeNewswire January 12, 2015

Advaxis and the GOG Foundation, Inc. to Collaborate on Global Phase 3 Clinical Trial of ADXS-HPV in Cervical Cancer

GlobeNewswire January 7, 2015

Biotechs to Follow in 2015 off Fresh Insider Moves

Accesswire January 6, 2015

Advaxis Submits Investigational New Drug Application to FDA for ADXS-HER2

GlobeNewswire January 5, 2015

Advaxis's Cancer Immunotherapies Featured on FOX News' Sunday Housecall

GlobeNewswire December 30, 2014

Advaxis Completes $17 Million Financing

GlobeNewswire December 19, 2014

Advaxis Announces FDA Acceptance of Its Investigational New Drug Application to Commence Clinical Trials of ADXS-HPV in Combination With MedImmune's MEDI4736 for the Treatment of HPV-Associated Cancers

GlobeNewswire December 15, 2014

Advaxis's Cancer Immunotherapies Featured on FOX News

GlobeNewswire December 12, 2014